Multimodality management of non-small cell lung cancer patients with brain metastases

Serena Ricciardi, Filippo De Marinis

Research output: Contribution to journalArticle

Abstract

Purpose of Review: Brain metastases are an important cause of morbidity and mortality, and are the most common intracranial tumors in adults. The prognosis of patients with brain metastases is very poor. The increasing incidence of brain metastases is directly related to the improvements in the treatment of systemic disease. Commonly, brain metastases are discovered after the diagnosis of cancer, often after other systemic metastases have developed.In this review article, we present the standard treatment approach and discuss new directions. Recent Findings: The most widely used treatment for patients with brain metastases is whole-brain radiotherapy. Actually, surgery and radiotherapy remain the principal therapeutic interventions. In contrast, the benefit of chemotherapy has long been viewed with skepticism.In an effort to improve the therapeutic ratio, radiosensitizers are often used concurrently with external-beam radiation: motexafin gadolinium and efaproxaril.Novel anticancer agents are under clinical investigation. Summary: The management of patients with brain metastases with non-small cell lung cancer has improved over time, due to the development of new treatment options and a better knowledge of prognostic factors.In the next 5 years, the results of several ongoing multicenter randomized trials will become available to further define the role of various radiation sensitizers and chemotherapeutic agents in combination with stereotactic radiosurgery, whole-brain radiation therapy, or both.

Original languageEnglish
Pages (from-to)86-93
Number of pages8
JournalCurrent Opinion in Oncology
Volume22
Issue number2
DOIs
Publication statusPublished - Mar 2010

Fingerprint

Non-Small Cell Lung Carcinoma
Neoplasm Metastasis
Brain
Radiotherapy
Therapeutics
Radiation-Sensitizing Agents
Radiosurgery
Antineoplastic Agents
Multicenter Studies
Neoplasms
Radiation
Morbidity
Drug Therapy
Mortality
Incidence

Keywords

  • Brain metastases
  • Non-small cell lung cancer
  • Surgery
  • Whole-brain radiation therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Multimodality management of non-small cell lung cancer patients with brain metastases. / Ricciardi, Serena; De Marinis, Filippo.

In: Current Opinion in Oncology, Vol. 22, No. 2, 03.2010, p. 86-93.

Research output: Contribution to journalArticle

@article{c76f73c01064479cb353e0186432ad23,
title = "Multimodality management of non-small cell lung cancer patients with brain metastases",
abstract = "Purpose of Review: Brain metastases are an important cause of morbidity and mortality, and are the most common intracranial tumors in adults. The prognosis of patients with brain metastases is very poor. The increasing incidence of brain metastases is directly related to the improvements in the treatment of systemic disease. Commonly, brain metastases are discovered after the diagnosis of cancer, often after other systemic metastases have developed.In this review article, we present the standard treatment approach and discuss new directions. Recent Findings: The most widely used treatment for patients with brain metastases is whole-brain radiotherapy. Actually, surgery and radiotherapy remain the principal therapeutic interventions. In contrast, the benefit of chemotherapy has long been viewed with skepticism.In an effort to improve the therapeutic ratio, radiosensitizers are often used concurrently with external-beam radiation: motexafin gadolinium and efaproxaril.Novel anticancer agents are under clinical investigation. Summary: The management of patients with brain metastases with non-small cell lung cancer has improved over time, due to the development of new treatment options and a better knowledge of prognostic factors.In the next 5 years, the results of several ongoing multicenter randomized trials will become available to further define the role of various radiation sensitizers and chemotherapeutic agents in combination with stereotactic radiosurgery, whole-brain radiation therapy, or both.",
keywords = "Brain metastases, Non-small cell lung cancer, Surgery, Whole-brain radiation therapy",
author = "Serena Ricciardi and {De Marinis}, Filippo",
year = "2010",
month = "3",
doi = "10.1097/CCO.0b013e3283350106",
language = "English",
volume = "22",
pages = "86--93",
journal = "Current Opinion in Oncology",
issn = "1040-8746",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Multimodality management of non-small cell lung cancer patients with brain metastases

AU - Ricciardi, Serena

AU - De Marinis, Filippo

PY - 2010/3

Y1 - 2010/3

N2 - Purpose of Review: Brain metastases are an important cause of morbidity and mortality, and are the most common intracranial tumors in adults. The prognosis of patients with brain metastases is very poor. The increasing incidence of brain metastases is directly related to the improvements in the treatment of systemic disease. Commonly, brain metastases are discovered after the diagnosis of cancer, often after other systemic metastases have developed.In this review article, we present the standard treatment approach and discuss new directions. Recent Findings: The most widely used treatment for patients with brain metastases is whole-brain radiotherapy. Actually, surgery and radiotherapy remain the principal therapeutic interventions. In contrast, the benefit of chemotherapy has long been viewed with skepticism.In an effort to improve the therapeutic ratio, radiosensitizers are often used concurrently with external-beam radiation: motexafin gadolinium and efaproxaril.Novel anticancer agents are under clinical investigation. Summary: The management of patients with brain metastases with non-small cell lung cancer has improved over time, due to the development of new treatment options and a better knowledge of prognostic factors.In the next 5 years, the results of several ongoing multicenter randomized trials will become available to further define the role of various radiation sensitizers and chemotherapeutic agents in combination with stereotactic radiosurgery, whole-brain radiation therapy, or both.

AB - Purpose of Review: Brain metastases are an important cause of morbidity and mortality, and are the most common intracranial tumors in adults. The prognosis of patients with brain metastases is very poor. The increasing incidence of brain metastases is directly related to the improvements in the treatment of systemic disease. Commonly, brain metastases are discovered after the diagnosis of cancer, often after other systemic metastases have developed.In this review article, we present the standard treatment approach and discuss new directions. Recent Findings: The most widely used treatment for patients with brain metastases is whole-brain radiotherapy. Actually, surgery and radiotherapy remain the principal therapeutic interventions. In contrast, the benefit of chemotherapy has long been viewed with skepticism.In an effort to improve the therapeutic ratio, radiosensitizers are often used concurrently with external-beam radiation: motexafin gadolinium and efaproxaril.Novel anticancer agents are under clinical investigation. Summary: The management of patients with brain metastases with non-small cell lung cancer has improved over time, due to the development of new treatment options and a better knowledge of prognostic factors.In the next 5 years, the results of several ongoing multicenter randomized trials will become available to further define the role of various radiation sensitizers and chemotherapeutic agents in combination with stereotactic radiosurgery, whole-brain radiation therapy, or both.

KW - Brain metastases

KW - Non-small cell lung cancer

KW - Surgery

KW - Whole-brain radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=76749165317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76749165317&partnerID=8YFLogxK

U2 - 10.1097/CCO.0b013e3283350106

DO - 10.1097/CCO.0b013e3283350106

M3 - Article

C2 - 20009927

AN - SCOPUS:76749165317

VL - 22

SP - 86

EP - 93

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

SN - 1040-8746

IS - 2

ER -